Back to results

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Primary Purpose

Relapsing Multiple Sclerosis

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

peginterferon beta-1a

About this trial

This is an interventional treatment trial for Relapsing Multiple Sclerosis focused on measuring Subcutaneous, Extension, Interferon, MS, PEGylated, Injectable, SC, PEG, peginterferon beta-1a, Relapsing

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

Must have completed the study treatment and visit schedule through Week 96 in Study 105MS301 (NCT00906399).

Key Exclusion Criteria:

Subjects exceeding more than 6 weeks since completion of the Week 96 visit of Study 105MS301 (NCT00906399).
Subjects with any clinically significant laboratory abnormalities, malignancies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease
Pregnant or nursing women.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

peginterferon beta-1a Q4W

peginterferon beta-1a Q2W

Arm Description

125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.

125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.

Outcomes

Primary Outcome Measures

Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs

AE: any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or may have required intervention to prevent one of the other outcomes listed in the definition above. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.

Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities

Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.

Number of Participants With Shifts From Baseline: Liver Function Laboratory Values

Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyl transferase.

Number of Participants With Shifts From Baseline: Kidney Function and Other Blood Chemistry

Number of Participants With Shifts From Baseline: Urinalysis

Shift to low includes normal to low, high to low, and unknown to low. Shift to high/positive includes normal to high/positive, low to high/positive, negative to high/positive, and unknown to high/positive. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. Pos=positive; RBC=red blood cells; WBC=white blood cells.

Secondary Outcome Measures

Annualized Relapse Rate (ARR)

Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of person-years followed in the period.

Percentage of Participants Who Relapsed

Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. New or recurrent neurologic symptoms that occur less than 30 days following the onset of a relapse were considered part of the same relapse. Participants who did not experience a relapse prior to switching to alternative MS medications, withdrew from study, or Amendment 3 (A3) took effect were censored at the time of switch/withdrawal/A3 effective date.

Number of New or Newly Enlarging T2 Hyperintense Lesions

The total number of new or newly enlarging T2 hyperintense lesions (from Study 105MS302 Baseline) as assessed by magnetic resonance imaging (MRI). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Number of New Active Lesions

The number of new active lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Number of New T1 Hypointense Lesions

The total number of new T1 hypointense lesions as assessed by MRI.

Number of Gd-Enhancing Lesions

The number of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Volume of T2 Hyperintense Lesions

The volume of T2 hyperintense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Volume of T1 Hypointense Lesions

The volume of T1 hypointense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Volume of Gd-Enhancing Lesions

The volume of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Percentage Change of Whole Brain Volume

Percentage change of whole brain volume as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Change From Baseline in Expanded Disability Status Scale (EDSS)

Change from Baseline in disability as measured by the Expanded Disability Status Scale (EDSS). The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Time to Sustained Disability Progression

Estimated proportion of participants with progression and time to progression based on the Kaplan-Meier product limit method. Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from 105MS302 baseline EDSS ≥ 1.0 that is sustained for 24 weeks, or at least a 1.5 point increase on the EDSS from 105MS302 baseline EDSS = 0 that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Participants were censored at the time of withdrawal/switch/A3 effective date if they withdrew from study, switched to alternative MS medication, or Amendment 3 took effect without a progression.

Change From Baseline in Symbol Digit Modalities Test (SDMT)

SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 (worst) to 110 (best).

Change From Baseline in Multiple Sclerosis Impact Scale (MSIS)-29 Physical Score

The 29-item MSIS-29 is a disease-specific participant-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Responses use a 5-point Likert scale ranging from 1 to 5. All questions are to be answered. The physical well being assessment portion of the MSIS-29 consists of 20 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 20-100. A lower total score indicates less physically-related impact while a higher total score indicates greater physically-related impact on a participant's functioning. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Change From Baseline in 12-Item Short Form Health Survey (SF-12) Mental Component Score (MCS)

The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. MCS computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Change From Baseline in SF-12 Physical Component Score (PCS)

The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. PCS was computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Change From Baseline in Euro Quality of Life (EQ-5D) Index Score

The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Scores of 1, 2, or 3 are possible responses for each of 5 questions (1=no problems, 2=some problems, 3=severe problems). A scoring formula developed by the EuroQol Group is then used to assign utility values for each participant's Health State Profile. A summary index score (EQ-5D index score) is derived from the 5 questions by conversion with this scoring formula and a table of scores. EQ-5D Summary Index values ranged from -0.6 (worst health state) to 1.00 (perfect health state). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Change From Baseline in EQ-5D Visual Analogue Scale (VAS)

The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Number of Relapses Requiring IV Steroid Use

Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Number of MS-Related Hospitalizations

Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: How Tolerable or Intolerable Do You Find the Medication?

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How tolerable or intolerable do you find the medication?" answers were numerically rated from 1 (extremely intolerable) to 10 (extremely tolerable). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication as Instructed?

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How convenient or inconvenient is it to take your medication as instructed?" answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication Every 2 Weeks?

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How convenient or inconvenient is it to take your medication every 2 weeks?" answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: Overall, How Satisfied or Dissatisfied Are You With This Medication?

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "Overall, how satisfied or dissatisfied are you with this medication?" answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: How Satisfied or Dissatisfied Are You With the Injection Frequency (Every 2 Weeks)?

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How satisfied or dissatisfied are you with the injection frequency (every 2 weeks)?" answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: How Likely Would You Be to Continue to Use This Medication?

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How likely would you be to continue to use this medication?" answers were numerically rated from 1 (extremely unlikely) to 10 (extremely likely). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS.

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: This Medication Makes It Easy For Me to Carry Out My Daily Responsibilities.

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "This medication makes it easy for me to carry out my daily responsibilities (ie, going to work, doing household chores or caring for my family)," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Makes It More Convenient for Me to Travel/Vacation.

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "The twice a month dosing makes it more convenient for me to travel/vacation," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Enables Me to Be More Spontaneous and Flexible.

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "The twice a month dosing enables me to be more spontaneous and flexible," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: This Medication Improves My Self-Confidence and Self-Reliance.

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "This medication improves my self-confidence and self-reliance," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: I Am Satisfied With the Dosing Frequency of This Medication.

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "I am satisfied with the dosing frequency (2 times per month) of this medication" answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: Over the Past 4 Weeks, Did You Miss Any of Your Injections?

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "Over the past 4 weeks, did you miss any of your injections?" answer choices were given as "none missed," "miss 1 injection," or "miss 2 injections." Data after Amendment 3 took effect are excluded.

Summary of Participant-Reported Treatment Satisfaction: Main Reason for Missed Injections

Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "Main reason for missed injections?" answer choices were given as "medication side effects," "injection pain," "forget to take medication," "tired of taking injections," "don't think medication is working," or "other." Data after Amendment 3 took effect are excluded.

Full Information

NCT ID

NCT01332019

First Posted

March 24, 2011

Last Updated

November 17, 2016

Sponsor

Biogen

1. Study Identification

Unique Protocol Identification Number

NCT01332019

Brief Title

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

Acronym

ATTAIN

Official Title

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Study Type

Interventional

2. Study Status

Record Verification Date

November 2016

Overall Recruitment Status

Completed

Study Start Date

April 2011 (undefined)

Primary Completion Date

October 2015 (Actual)

Study Completion Date

October 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Biogen

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Relapsing Multiple Sclerosis

Keywords

Subcutaneous, Extension, Interferon, MS, PEGylated, Injectable, SC, PEG, peginterferon beta-1a, Relapsing

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

1077 (Actual)

8. Arms, Groups, and Interventions

Arm Title

peginterferon beta-1a Q4W

Arm Type

Experimental

Arm Description

125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.

Arm Title

peginterferon beta-1a Q2W

Arm Type

Experimental

Arm Description

125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.

Intervention Type

Drug

Intervention Name(s)

peginterferon beta-1a

Other Intervention Name(s)

PEGylated Interferon beta-1a, Plegridy, PEG IFN β-1a, BIIB017

Intervention Description

Administered as specified in the treatment arm

Primary Outcome Measure Information:

Title

Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs

Description

Time Frame

up to 4 years

Title

Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities

Description

Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.

Time Frame

up to 4 years

Title

Number of Participants With Shifts From Baseline: Liver Function Laboratory Values

Description

Time Frame

Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years

Title

Number of Participants With Shifts From Baseline: Kidney Function and Other Blood Chemistry

Description

Time Frame

Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years

Title

Number of Participants With Shifts From Baseline: Urinalysis

Description

Time Frame

Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years

Secondary Outcome Measure Information:

Title

Annualized Relapse Rate (ARR)

Description

Time Frame

up to 4 years

Title

Percentage of Participants Who Relapsed

Description

Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. New or recurrent neurologic symptoms that occur less than 30 days following the onset of a relapse were considered part of the same relapse. Participants who did not experience a relapse prior to switching to alternative MS medications, withdrew from study, or Amendment 3 (A3) took effect were censored at the time of switch/withdrawal/A3 effective date.

Time Frame

Up to 4 years

Title

Number of New or Newly Enlarging T2 Hyperintense Lesions

Description

Time Frame

Week 48, Week 96

Title

Number of New Active Lesions

Description

The number of new active lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Time Frame

Week 48, Week 96

Title

Number of New T1 Hypointense Lesions

Description

The total number of new T1 hypointense lesions as assessed by MRI.

Time Frame

Week 48, Week 96

Title

Number of Gd-Enhancing Lesions

Description

The number of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Time Frame

Baseline (start of 105MS302), Week 48, Week 96

Title

Volume of T2 Hyperintense Lesions

Description

The volume of T2 hyperintense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Time Frame

Baseline (start of 105MS302), Week 48, Week 96

Title

Volume of T1 Hypointense Lesions

Description

The volume of T1 hypointense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Time Frame

Baseline (start of 105MS302), Week 48, Week 96

Title

Volume of Gd-Enhancing Lesions

Description

The volume of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Time Frame

Baseline (start of 105MS302), Week 48, Week 96

Title

Percentage Change of Whole Brain Volume

Description

Percentage change of whole brain volume as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.

Time Frame

Baseline (start of 105MS302), Week 48, Week 96

Title

Change From Baseline in Expanded Disability Status Scale (EDSS)

Description

Time Frame

Baseline (start of 105MS302), Weeks 12, 24, 48, 72, 96, 120, 144, 168

Title

Time to Sustained Disability Progression

Description

Time Frame

Weeks 12, 24, 28, 72, 96, 120, 144, 168

Title

Change From Baseline in Symbol Digit Modalities Test (SDMT)

Description

Time Frame